Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
  • A61K31/05—Phenols
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/075—Ethers or acetals
  • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
  • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/365—Lactones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
  • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/34—Alcohols
  • A61K8/347—Phenols
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
  • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/60—Sugars; Derivatives thereof
  • A61K8/602—Glycosides, e.g. rutin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/16—Emollients or protectives, e.g. against radiation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/06—Free radical scavengers or antioxidants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2200/00—Function of food ingredients
  • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2250/00—Food ingredients
  • A23V2250/30—Other Organic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• the present invention relates to the field of medicine.
• the present invention relates to the field of compositions and methods for preventing, ameliorating or reducing radiation-induced diseases.
• X and y rays damage cells mainly by direct ionization of DNA and other cellular targets and by indirect effects through reactive oxygen species (ROS).
• ROS reactive oxygen species
• Gamma rays originate from the settling process of an excited nucleus of a radionuclide after it undergoes radioactive decay whereas X-rays are produced when electrons strike a target or when electrons rearrange within an atom.
• X and y rays are both types of high energy (high frequency) electromagnetic radiation. They are packets of energy (photons) that have no charge or mass. Both, X and y rays have the same properties and health effects.
• Electromagnetic radiation including X-rays and y-rays, damages the cells directly by ionization of DNA and other molecules, and also indirectly by the generation of reactive oxygen species.
• the response to radiation exposure depends on the cell type and dose of radiation, inherent tissue sensitivity and repair, and modulating intracellular factors that include cell cycle status, O2 pressure, and levels of thiols and other antioxidants.
• the radiation protection and mitigation strategies are scarce and inefficient. Annually, millions of cancer patients undergo radiotherapy during their course of treatment and some radiological or nuclear events in recent years pose a threat to people, hence the need for radiation protection or mitigation strategies.
• Radioprotectors are compounds that can reduce the direct damage caused by radiation. Radiomitigators are compounds that are able to minimize toxicity even after radiation has been delivered. In general, ideal radioprotectors or radiomitigators should be stable, with the possibility of an easy administration, with no relevant toxicity, and should protect normal tissues that are considered sensitive such that acute or late toxicities in these tissues are either dose-limiting or responsible for a significant reduction in quality of life (causing e.g. mucositis, pneumonitis, myelopathy, xerostomia, proctitis, fibrosis, or leukoencephalopathy).
• a wide range of phytochemicals are antioxidants and, thus, potentially radioprotective.
• their radioprotective or radiomitigator properties are usually effective during a short period of time, usually limited to a maximum of one month after radiation occurred. Therefore, new compounds and compositions that are able to treat, reduce, prevent or ameliorate the harmful effect of radiation in a subject during a continued period of times are desirable.
• the present invention provides compositions and uses thereof for the long-term protection and mitigation of diseases caused by radiation exposure.
• FIG. 1 A) Radiation dose-response for a 30-day survival test in Swiss albino mice subjected to whole-body y irradiation B) Sixty-days survival of mice treated with y rays (LD50/30) and pterostilbene (PT) at different doses. Amifostine was used as a control approved radioprotector C) Sixty-days survival of mice treated with y rays (LD50/30) and resveratrol (Resv) at different doses. Compounds were administered orally. In all cases, twenty mice were used per group.
• FIG. 1 Combination of pterostilbene (PT) and other polyphenols to prevent the lethality induced by y radiation (LD50/30) at A) 6 days, B) 30 days and C) 60 days post-irradiation. Doses for each phytochemical were selected from the max non-toxic doses published. Compounds were administered orally. In all cases, twenty mice were used per group.
• PT pterostilbene
• Figure 3 A) Effect of the combination of pterostilbene (PT) and silibinin (SIL) on the long-term survival of mice subjected to whole-body y irradiation (LD50/30). B) Radioprotection elicited by the combination of PT and SIL: Comparison between administration of the polyphenols before or after the y irradiation. Compounds were administered IP. In all cases, twenty mice were used per group.
• PT pterostilbene
• SIL silibinin
• Figure 4 A) Effect of pterostilbene (PT) and silibinin (SIL) on the survival of y-irradiated (LD50/30) mice and the effect on body weight. B) Effect of PT and SIL administration on the whole-body y radiation-induced alteration of neuromotor functions in mice. Compounds were administered via IP. In all cases, twenty mice were used per group.
• PT pterostilbene
• SIL silibinin
• FIG. 1 Protective effect of pterostilbene (PT) and silibinin (SIL) on the y radiation- induced oxidative damage expresion (RT-PCR) of different antioxidant defense-related enzyme activities in isolated cells.
• GCL g-glutamyl-cysteine ligase
• GPX glutathione peroxidase
• CAT catalase
• SOD superoxide dismutase
• Figure 6 Protective effect of pterostilbene (PT) and silibinin (SIL) on the y radiation- induced oxidative damage in different molecular markers.
• PT pterostilbene
• SIL silibinin
• PT pterostilbene
• SIL silibinin
• Figure 9. Effect of nicotinamide riboside (NR) and fibroblast-stimulating lipopeptide (FSL-1 ) on the y irradiation (LD50/30)-induced mortality.
• NR was administered daily for 30 days, one single dose (oral) per day, and starting right after (60 min) the irradiation.
• FSL-1 was administered IP, only once, 24 h after the irradiation. In all cases, twenty mice were used per group.
• FIG. 10 A) Pterostilbene (PT), B) Silibinin (SIL) and C) NAD+ levels in the circulating blood of treated and irradiated mice (6 mice per group in all cases).
• PT Pterostilbene
• SIL Silibinin
• Figure 11 Addition of potential radiomitigators (nicotinamide riboside, NR; and fibroblast-stimulating lipopeptide-1 , FSL-1 ) to the radioprotective combination of pterostilbene (PT) and silibinin (SIL).
• Figure 14 Effect of radioprotectors and radiomitigators on cellular NAD+ content, DNA damage, and hematopoietic recovery in y -irradiated mice.
• A) Effect of PT, SIL, NR and the specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) FK866 on the NAD+ content of cells isolated from y -irradiated mice (n 5 per group, cell type, and treatment). FK866 was administered in vivo (15 mg/kg, twice daily by intraperitoneal injection, during 6 days and starting 3 days prior to irradiation, see Fig. 11 a), and was also present in the cell cultures (100 nM).
• NAMPT nicotinamide phosphoribosyltransferase
• C) Effect of PT, SIL, NR and FK866 on the DNA damage in cells isolated from y - irradiated mice (n 5 per group, cell type, and treatment). Statistical analyses were performed using Student’s t-test (P ⁇ 0.01 ; ‘comparing all groups vs. y-irradiated controls; +comparing y-irradiated groups where FK866 was present vs. their respective controls). Mice were treated and cells isolated as above (a). D) Effect of PT, SIL, NR and FSL1 on the hematopoietic recovery in y -irradiated mice.
• CFU-GM colony forming unit-granulocyte, macrophage
• CFU-GEMM colony forming unit-granulocyte, erythroid, macrophage, megakaryocyte
• Figure 15 Effect of the treatment with pterostilbene and silibinin on Nrf2-, NF-kB-, PARP1 - and PGC1 a-dependent mechanisms.
• Epithelial intestinal cells were isolated, right before the irradiation, from mice subjected to the protocol displayed in Fig. 11 a.
• Densitometric analysis represents the mean values ⁇ SD for 5-6 different mice per molecule and experimental condition (P ⁇ 0.01 ; ‘comparing PT-, SIL- or PT+SIL-treated mice versus physiological saline, PS-treated mice, +comparing PT+SIL- versus PT-treated mice; #comparing PT+SIL- versus SIL-treated mice).
• Isolated lECs were cultured for 24 h in the presence or in the absence of specific siRNAs, and thereafter were irradiated with y rays (same dose used for the in vivo experiments), d Cell death was analyzed, as described under Methods, in isolated and cultured IEC cells 12 h after y irradiation.
• PT (20 pM) and SIL (15 pM) were present in the cultures containing lECs isolated from PT+SIL-treated mice. Thereby, the effects induced by the in vivo treatment could be preserved under in vitro conditions.
• Data are mean values ⁇ SD for 4-5 different experiments per molecule and experimental condition (p ⁇ 0.01 ; ‘comparing, under PS or PT+SIL, treatment with a specific siRNA versus controls -treatment with vehicle-; p ⁇ 0.01 ; +comparing data under PT+SIL versus their equivalents under PS).
• the present invention relates to a composition
• a composition comprising a) Pterostilbene, or a salt thereof, and b) Silibinin, or a salt thereof.
• the composition further comprises at least one or more radiomitigator compound/s, preferably selected from a) NAD+ booster, and/or b) Fibroblast-Stimulating Lipopeptide-1 , or any salts thereof.
• the composition further comprises at least two or more radiomitigators compounds, wherein the at least two or more radiomitigator compounds are a NAD+ booster and Fibroblast-Stimulating Lipopeptide-1 , or any salts thereof.
• the Pterostilbene is Pterostilbene phosphate disodium salt and/or the Silibinin is silibinin-C-2',3-dihydrogen succinate, disodium salt.
• the NAD+ booster is Nicotinamide Riboside.
• the composition is a pharmaceutical, nutraceutical, cosmetic or food composition.
• the present invention relates to a Pterostilbene, or a pharmaceutically acceptable salt thereof, for use in the prevention, amelioration or reduction of diseases induced by ionizing radiation in a subject, in combination with Silibinin, or a pharmaceutically acceptable salt thereof, wherein the administration is carried out before the radiation, or after the radiation, or during the radiation; and wherein the combination is herein understood as the simultaneous or sequential administration, in any order, of a) Pterostilbene, or a pharmaceutically acceptable salt thereof, and b) Silibinin, or a pharmaceutically acceptable salt thereof, to said subject.
• the Pterostilbene, or a pharmaceutically acceptable salt thereof, and Silibinin, or a pharmaceutically acceptable salt thereof are administered in a sole pharmaceutical composition or in separate pharmaceutical compositions.
• the administration of Pterostilbene, or a pharmaceutically acceptable salt thereof, and Silibinin, or a pharmaceutically acceptable salt thereof is topical, oral or parenteral.
• the Pterostilbene, or a pharmaceutically acceptable salt thereof, and Silibinin, or a pharmaceutically acceptable salt thereof are administrated several times simultaneously or sequentially before and/or after radiation, or both.
• the combination is in a dosage capable of providing a radioprotective effect.
• the use further comprises the administration in combination with at least one or more radiomitigator compound/s, wherein the combination is herein understood as the simultaneous or sequential administration of a) Pterostilbene, or a pharmaceutically acceptable salt thereof, b) Silibinin, or a pharmaceutically acceptable salt thereof, and c) at least one or more radiomitigator compound/s, or any pharmaceutically acceptable salt thereof, to said subject.
• the combination is herein understood as the simultaneous or sequential administration of a) Pterostilbene, or a pharmaceutically acceptable salt thereof, b) Silibinin, or a pharmaceutically acceptable salt thereof, and c) at least one or more radiomitigator compound/s, or any pharmaceutically acceptable salt thereof, to said subject.
• the at least one or more radiomitigator compound/s is a NAD+ booster and/or a Fibroblast-Stimulating Lipopeptide, or any pharmaceutically acceptable salts thereof.
• the use further comprises the administration in combination with at least two or more radiomitigator compounds, wherein the at least two or more radiomitigator compounds are NAD+ booster and Fibroblast-Stimulating Lipopeptide, or any pharmaceutically acceptable salts thereof.
• the NAD+ booster is Nicotinamide Riboside.
• the diseases induced by ionizing radiation are related to DNA damage, radiation-induced cytotoxicity, genotoxicity and/or oxidative cellular damage, more preferably acute radiation syndrome and/or chronic radiation syndrome.
• the ionizing radiation is gamma rays or X-rays.
• the Pterostilbene is Pterostilbene phosphate disodium salt and/or the Silibinin is silibinin-C-2',3-dihydrogen succinate, disodium salt.
• the present invention relates to a non-therapeutic cosmetic use of Pterostilbene, or a salt thereof, in combination with Silibinin, or a salt thereof, wherein the combination is herein understood as the simultaneous or sequential administration, in any order, of a) Pterostilbene, or a salt thereof, and b) Silibinin, or a salt thereof, to said subject.
• the use is to protect, ameliorate and/or reduce the adverse effects of the sun on human skin and lips, such as age spots, sunburn, sun spots, lines, fine lines, wrinkles, crow's feet, spider veins, stretch marks, dark eye circles, hyperpigmentation, hypopigmentation, discoloration, uneven skin tone, dullness, freckles, skin breakout, blemishes, skin fragility, dryness, patchiness, tactile roughness, chapping, sagginess, thinning, enlarged pores.
• the present invention relates to a Pterostilbene, or a salt thereof, in combination with Silibinin, or a salt thereof, for use to increase the intracellular levels of Sirtuins in a patient in need thereof, wherein said increase is as compared to the intracellular levels of Sirtuins in the same patient before treatment with Pterostilbene, or a salt thereof, in combination with Silibinin, or a salt thereof.
• the patient in need thereof is a patient suffering from a neurodegenerative, cardiovascular, pulmonary, metabolic, or aged-related disorders.
• the disorder is selected from the list consisting of Alzheimer or other dementias or cognitive impairment associated to aging, Parkinson, Huntington disease, Multiple sclerosis, Kennedy disease (Spinal and bulbar muscular atrophy), kidney disease, cerebrovascular disease, hypertension, Chronic obstructive pulmonary disease, Amyotrophic lateral sclerosis and Diabetes.
• the present invention relates to a Pterostilbene, or a salt thereof, in combination with Silibinin, or a salt thereof, for use as a nutraceutical composition, wherein the combination is herein understood as the simultaneous or sequential administration, in any order, of a) Pterostilbene, or a salt thereof, and b) Silibinin, or a salt thereof, to said subject.
• the use as a nutraceutical composition is for the treatment or prevention of diseases induced by ionizing radiation, for the treatment or prevention of neurodegenerative, cardiovascular, pulmonary, metabolic, or aged- related disorders, and/or for the protection or repairment of the adverse effects of the sun on human skin or lips.
• the diseases induced by ionizing radiation are related to DNA damage, radiation-induced cytotoxicity, genotoxicity and/or oxidative cellular damage.
• the neurodegenerative, cardiovascular, pulmonary, metabolic, or aged-related disorder is selected from the list consisting of Alzheimer or other dementias or cognitive impairment associated to aging, Parkinson, Huntington disease, Multiple sclerosis, Kennedy disease (Spinal and bulbar muscular atrophy), kidney disease, cerebrovascular disease, hypertension, Chronic obstructive pulmonary disease, Amyotrophic lateral sclerosis and Diabetes.
• the adverse effects of the sun on human skin or lips are selected from the list consisting of age spots, sunburn, sun spots, lines, fine lines, wrinkles, crow's feet, spider veins, stretch marks, dark eye circles, hyperpigmentation, hypopigmentation, discoloration, uneven skin tone, dullness, freckles, skin breakout, blemishes, skin fragility, dryness, patchiness, tactile roughness, chapping, sagginess, thinning, enlarged pores, cellulite formation, acne formation, rosacea, psoriasis, and eczema.
• the present invention relates to a kit of parts comprising at least two recipients comprising at least Pterostilbene, or a salt thereof, and Silibinin, or a salt thereof, and optionally at least one or more radiomitigator compound/s.
• the optionally at least one or more radiomitigator compound/s is selected from the group of a) NAD+ boosters, and/or b) Fibroblast-Stimulating Lipopeptide, or any pharmaceutically acceptable salts thereof.
• the NAD+ booster is Nicotinamide Riboside.
• the Pterostilbene is Pterostilbene phosphate disodium salt and/or the Silibinin is sil ibin in-C-2' , 3-d ihydrogen succinate, disodium salt.
• the conjunctive term "and/or" between multiple recited elements is understood as encompassing both individual and combined options. For instance, where two elements are conjoined by "and/or", a first option refers to the applicability of the first element without the second. A second option refers to the applicability of the second element without the first. A third option refers to the applicability of the first and second elements together. Any one of these options is understood to fall within the meaning, and therefore satisfy the requirement of the term "and/or” as used herein. Concurrent applicability of more than one of the options is also understood to fall within the meaning, and therefore satisfy the requirement of the term "and/or.”
• disease as used herein is intended to be generally synonymous, and is used interchangeably with, the terms “pathology”, “disorder” and “condition” (as in medical condition), in that all reflect an abnormal condition of the body or of one of its parts that impairs normal functioning and is typically manifested by distinguishing signs and symptoms.
• a “therapeutically effective amount” as referred herein is defined as an amount of a compound that, when administered to a subject, is sufficient to effect such treatment of a conditioned state.
• the “therapeutically effective amount” may vary depending on the compound, and condition being treated, the age and relative health of the subject, the route and form of administration, the judgment of the one having ordinary skill in the art, and other factors.
• treatment refers to the medical care given to a patient for a disease or injury. This term includes curing the disease but also ameliorating, mitigating, or reducing the symptoms of said disease.
• therapeutic treatment or “treatment” as used herein refers to bringing a body from a pathological state or disease back to its normal, healthy state.
• therapeutic treatment or “treatment” as used herein, also refers to the mitigation, amelioration, or reduction of the harmful effect of radiation in a subject, or in some manner reducing the symptoms associated with such effects.
• prophylactic treatment refers to preventing a pathological state.
• prevention is meant keeping the disease from happening.
• amelioration is meant an improvement in a patient's disease, or the activity of making an effort to correct, or at least make more acceptable said disease.
• reduction or “mitigation” is meant decreasing the severity, seriousness or painfulness of the disease.
• subject refers to a mammalian subject.
• it is selected from a human, companion animal, non-domestic livestock or zoo animal.
• the subject may be selected from a human, dog, cat, cow, pig, sheep, horse, bear, and so on.
• said mammalian subject is a human subject.
• ionizing radiation is meant the radiation consisting of particles, X-rays, or gamma rays with sufficient energy to cause ionization in the medium through which it passes.
• y rays or “y radiation” is meant a penetrating form of electromagnetic radiation arising from the radioactive decay of atomic nuclei. It consists of the shortest wavelength electromagnetic waves and so imparts the highest photon energy.
• X- rays or X radiation is meant or X-radiation, is a penetrating form of high-energy electromagnetic radiation. Most X-rays have a wavelength ranging from 10 picometers to 10 nanometers, corresponding to frequencies in the range 30 petahertz to 30 exahertz and energies in the range 124 eV to 124 keV.
• Pterostilbene or PT is meant 3,5-dimethoxy-4’-hydroxystilbene or a salt, solvate, isomer (enantiomers, diastereomers), hydrate, or any known derivatives, synthetic variants and acceptable formulations (such as pharmaceutical, cosmetical, nutraceutical) thereof.
• Pterostilbene (PT) is a natural antioxidant and a natural analogue of Resveratrol, but almost 60-100 times more potent antifungal agent that shows similar anticarcinogenic properties. It is present predominantly in blueberries and red grapes, although quantitative studies show that for every 10 parts of t- Resveratrol, there are only 1 -2 parts of t-Pterostilbene.
• Pterostilbene corresponds to the formula:
• Silibinin or SIL also known as silybin or silymarin (both from Silybum (milk thistle) is a flavonoid obtain from a genus of two species of thistles in the daisy family. Silibinin includes any a salt, solvate, isomer (enantiomers, diastereomers), hydrate, or any known derivatives, synthetic variants and acceptable formulations (such as pharmaceutical, cosmetical, nutraceutical) thereof. The plants are native to the Mediterranean regions of Europe, North Africa, and the Middle East.
• Silibinin is the major active constituent of silymarin, a standardized extract of the milk thistle seeds, containing a mixture of flavonolignans consisting of silibinin, isosilibinin, silichristin, silidianin, and others. Silibinin itself is a mixture of two diastereomers, silybin A and silybin B, in approximately equimolar ratio. SIL is also known as 3,5,7- trihydroxy-2-[3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1 ,4- benzodioxin-6-yl]-2,3-dihydrochromen-4-one with the following formula:
• Nicotinamide adenine dinucleotide booster NAD+ precursors or NAD+ boosters is meant any compound as clearly disclosed on the document by Rajman et al., Cell Metab. 2018 March 06; 27(3): 529-547. doi: 10.1016/j.cmet.2O18.02.011 , such as NAD precursors, activators of NAD synthesis, or inhibitors of NAD+ degradation. Nicotinamide includes any a salt, solvate, isomer (enantiomers, diastereomers), hydrate, or any known derivatives, synthetic variants and acceptable formulations (such as pharmaceutical, cosmetical, nutraceutical) thereof.
• Fibroblast-Stimulating Lipopeptide or FSL-1 is meant the Toll-Like Receptor 2/6 Agonist, or salt, solvate, isomer (enantiomers, diastereomers), hydrate, or any known derivatives, synthetic variants and acceptable formulations (such as pharmaceutical, cosmetical, nutraceutical) thereof, and corresponds to the formula:
• Nicorinamide riboside is meant a pyridine-nucleoside similar to vitamin B3, functioning as a precursor to nicotinamide adenine dinucleotide or NAD+.
• the formula of NR is:
• kit of parts refers to a combined preparation wherein the active ingredients are physically separated for use in a combined therapy by simultaneous administration or sequential administration to the patient.
• the radioprotective effect of a compound is negatively affected by the co-administration of another compound. This is shown in Figure 2C, where the radioprotective effect of PT provides a 40% survival after 60 days, and Gallic acid provides around 5% protection. However, when both compounds are combined, the overall rate of survival is around 35%, resulting in a reduced radioprotective effect than the administration of PT alone.
• the radioprotective effect of two compounds is summed when they are combined, resulting in a protection derived of their individual effects added together.
• Figure 2C it is shown that the protection provided by PT is around 40%, and the protection provided by Genistein is around 7%.
• the resulting protection amounts to around 45%, which means that both compounds are exerting their effect and the overall protection is, more or less, the sum of the effects of both compounds.
• the resulting radioprotection can be worse, can be the same or the sum of the two compounds, but that also, some compounds combined together provide with a synergistic effect and an enhanced protection that is not derivable from the mere sum of their radioprotective properties.
• PT and SIL when PT and SIL are combined with other radiomitigator compounds, such as nicotinamide riboside (NR) or fibroblast-stimulating lipopeptide-1 (FSL-1 ), the survival is even further increased to up to 50-60% after a year and, remarkably, when the four compounds (PT, SIL, NR and FSL-1 ) are combined, they provide a nearly full protection (90%) of the animals after 360 days.
• NR nicotinamide riboside
• FSL-1 fibroblast-stimulating lipopeptide-1
• the present invention provides two main findings: on the one hand, it was found that the co-administration of PT and SIL, two natural compounds with radioprotective properties, provide an enhanced and durable synergistic radioprotection not derived from the mere accumulation of their corresponding radioprotective effects. On the other hand, it was also found that the combination of these two compounds with a radiomitigator compound, such as NR and/or FSL-1 , can further enhance the protection to radiation up to 90% of survival for long period of times, even for a year.
• a radiomitigator compound such as NR and/or FSL-1
• the authors further investigated the potential signaling pathways that may be involved in the protective effect elicited by the combination of PT+SIL. As shown in Fig.
• Pterostilbene for use in the prevention, amelioration or reduction of diseases induced by ionizing radiation.
• a first aspect of the present invention relates to a Stilbenoid, preferably Resveratrol or Pterostilbene, or a pharmaceutically acceptable salt or derivative thereof, for use in the treatment, prevention, amelioration or reduction of diseases induced by ionizing radiation in a subject, in combination with Silibinin, or a pharmaceutically acceptable salt or derivative thereof.
• the Stilbenoid used is Pterostilbene or a pharmaceutically acceptable salt thereof.
• the present invention provides Pterostilbene, or a pharmaceutically acceptable salt thereof, for use in the treatment, prevention, amelioration or reduction of diseases induced by ionizing radiation in a subject, in combination with Silibinin, or a pharmaceutically acceptable salt thereof, wherein the administration is carried out before the radiation, or after the radiation, or during the radiation; and wherein the combination is herein understood as the simultaneous or sequential administration, in any order, of a) Pterostilbene, or a pharmaceutically acceptable salt thereof, and b) Silibinin, or a pharmaceutically acceptable salt thereof, to said subject.
• the diseases induced by ionizing radiation are related to DNA damage, radiation-induced cytotoxicity, genotoxicity and/or oxidative cellular damage.
• the diseases induced by the ionizing radiation are acute radiation syndrome and/or chronic radiation syndrome.
• said diseases are selected from the group consisting of skin diseases, acute radiation syndrome, cancer and cardiovascular diseases.
• Pterostilbene is used in combination with Silibinin.
• PT and SIL may be administered in a sole composition or in separate compositions.
• the Pterostilbene is Pterostilbene phosphate disodium salt.
• the Silibinin is silibinin-C-2',3-dihydrogen succinate, disodium salt.
• PT and SIL are administered in combination to prevent, ameliorate or reduce diseases induced by ionizing radiation in a subject.
• the subject is a mammal. More preferably, the subject is a human being.
• the administration can be simultaneous (at the same time) or sequential.
• “Sequential administration” as used herein refers to the administration of SIL or a composition comprising thereof shortly before or after administration of PT or a composition comprising thereof.
• “Shortly before or after” as used herein is understood as within an interval of 1 to 24 hours, preferably 1 to 12 hours, preferably 1 to 3 hours, preferably within 2 hours, more preferably within 1 hour or less, such as within 45 minutes, 30 minutes, 15 minutes or less.
• PT is administered first followed by SIL.
• SIL is administered first followed by PT.
• PT and SIL administration is carried out simultaneously.
• the PT and SIL are administered in combination simultaneously, as a part of a single composition or as part of two different compositions.
• said pharmaceutically acceptable compounds and compositions are formulated to be compatible with its intended route of administration.
• Methods to accomplish the administration are known to those of ordinary skill in the art. This includes, for example, injections, by parenteral routes such as intravascular, intravenous, intraarterial, subcutaneous, intramuscular, intraperitoneal, intraventricular, intraepidural, or others as well as oral, topical, nasal, ophthalmic, rectal, or topical. Sustained release administration is also specifically contemplated, by such means as depot injections or erodible implants.
• a preferred route of administration is parenteral administration, which is herein understood as the administration within a vessel or vessels and typically includes intravenous or intraarterial administration. Currently, the most preferred route of administration is parenteral, oral or topical.
• the administration can be carried out only once, or there can be more than one administration. In a preferred embodiment, there compounds are administered several times. In a particular embodiment, the administration may comprise at least one, two, three, four, five, six, seven or more doses.
• the administration can be performed before, during or after the radiation occurs.
• the administration can be performed at least 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 days before the radiation occurs.
• the administration occurs after radiation.
• the administration carried out after the radiation occurs 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10 or more than 10 days, such as 20 or 30 days, or more than one moth, such as 2, 3, 5, 6, 8, 9 months after radiation.
• the administration is carried out on the same day where the radiation occurs, either before or after it.
• the administration consists of several doses administered during several days before, on the same day, and/or after the radiation occurs.
• Pterostilbene and Silibinin, or any pharmaceutically acceptable salts thereof are administrated several times simultaneously or sequentially before and/or after radiation, or both.
• PT and SIL for use according to the first aspect of the present invention are administered in a dosage capable of providing a radioprotective effect.
• radioprotection is understood the ability to reduce the direct damage caused by radiation. Accordingly, in the present invention, the dosage of PT and SIL is not particularly restricted.
• PT is administered at a dosage up to 500 mg/kg.
• PT may be administered at dosages ranging from 300 mg/kg to 30 mg/kg.
• PT is administered at a dosage from 200 mg/kg to 40 mg/kg or 150 mg/kg to 40 mg/kg. More preferably, PT is administered at a dosage of 100 mg/kg.
• PT, or a pharmaceutically acceptable salt thereof is administered to a human at a dosage up to 40.65 mg/kg.
• PT may be administered to humans at dosages ranging from 24,39 mg/kg to 2.43 mg/kg.
• PT is administered to humans at a dosage from 16.2 mg/kg to 3.25 mg/kg or 12.19 mg/kg to 3.25 mg/kg. More preferably, PT is administered to humans at a dosage of 8.13 mg/kg.
• SL, or a pharmaceutically acceptable salt thereof is administered at a dosage up to 500 mg/kg.
• SIL may be administered at a dosage ranging from 200 mg/kg to 35 mg/kg.
• SIL is administered at a dosage from 150 mg/kg to 40 mg/kg or 100 mg/kg to 50 mg/kg.
• PT is administered at a dosage of 70 mg/kg or the equivalent for humans.
• SL, or a pharmaceutically acceptable salt thereof is administered to humans at a dosage up to 40.65 mg/kg.
• SIL may be administered to humans at a dosage ranging from 16.26 mg/kg to 2.84 mg/kg.
• SIL is administered to humans at a dosage from 12.19 mg/kg to 3.25 mg/kg or 8.13 mg/kg to 4.06 mg/kg. More preferably, PT is administered to humans at a dosage of 5.69 mg/kg or the equivalent for humans. Administration of further compounds
• the use described in any of the above mentioned embodiments further comprises the administration in combination with at least one further radiomitigator compound, wherein the use described herein is herein understood as the simultaneous or sequential administration of a) Pterostilbene, or a pharmaceutically acceptable salt thereof, b) Silibinin, or a pharmaceutically acceptable salt thereof, and c) one or more radiomitigator compounds, to said subject.
• the at least one or more radiomitigator compound/s refers to a nicotinamide adenine dinucleotide booster (referred from now on as NAD+ boosters), and/or a Fibroblast-Stimulating Lipopeptide-1 (referred from now on as FSL-1 ), or any pharmaceutically acceptable salt thereof.
• NAD+ boosters nicotinamide adenine dinucleotide booster
• FSL-1 Fibroblast-Stimulating Lipopeptide-1
• FSL-1 Fibroblast-Stimulating Lipopeptide-1
• a “radiomitigator” is a compound that is able to minimize toxicity after even after radiation has been delivered.
• the administration of PT combined with SIL further comprises the administration of one or more radiomitigator compound/s.
• the combinations between PT, SIL and the one or more radiomitigator compound/s are not limited, that is, PT can be administered in a single composition together with SIL and one or more radiomitigator/s, or they can be administered individually in different compositions. All the possible combinations of the three (or four or more) compounds are included herein.
• the use of PT in the prevention, amelioration or reduction of diseases induced by ionizing radiation in a subject, in combination with SIL, their salt or derivative thereof further comprises the administration of a NAD+ booster.
• the at least three compounds are administered together, and can be comprised in the same or in different compositions and can be administered sequentially or simultaneously.
• the use of PT in the prevention, amelioration or reduction of diseases induced by ionizing radiation in a subject, in combination with SIL, their salt or derivative thereof further comprises the administration of FSL-1 .
• the at least three compounds are administered together, and can be comprised in the same or in different compositions and can be administered sequentially or simultaneously.
• the use of PT in the prevention, amelioration or reduction of diseases induced by ionizing radiation in a subject, in combination with SIL, their salts or derivatives thereof further comprises the administration of both a NAD+ booster and FSL-1 .
• the four compounds are and can be comprised in the same or in different compositions and can be administered sequentially or simultaneously.
• the NAD+ booster is Nicotinamide riboside or 1 -(
• the use of PT in the prevention, amelioration or reduction of diseases induced by ionizing radiation in a subject, in combination with SIL, their salts or derivatives thereof further comprises the administration of NR and FSL-1.
• the four compounds are administered together, in one or more than one doses, comprised in the same or in different compositions, and administered sequentially or simultaneously before, during or after the radiation.
• PT and SIL are administered once per day during several days before the radiation and/or several days after the radiation. More preferably, PT and SIL are administered daily during 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 , preferably 5, days before the radiation. In another embodiment, PT and SIL are administered daily before the radiation and up to 5, 4, 3, 2, 1 days after the radiation. Preferably, PT and SIL are administered daily during the 5 previous days before the radiation and during the 2 days after radiation.
• the NAD+ booster is administered once per day on the same day of the radiation and during the next month after radiation. In another embodiment, the NAD+ booster is administered at least 60 mins after the radiation and it is further administered during the next 30 days after the radiation.
• the FSL-1 is administered only once, preferably after the radiation, more preferably at least one day after the radiation.
• the NAD+ booster, or a pharmaceutically acceptable salt thereof is administered at a dosage up to 500 mg/kg. In an embodiment, the NAD+ booster, or a pharmaceutically acceptable salt thereof, is administered at a dosage from 400 mg/kg to 100mg/kg. Preferably, the NAD+ booster is administered at a dosage from 300 mg/kg to 150 mg/kg or 200 mg/kg to 150 mg/kg. More preferably, the NAD+ booster is administered at a dosage of 185 mg/kg. In an embodiment, the NAD+ booster, or a pharmaceutically acceptable salt thereof, is administered to humans at a dosage up to 40.65 mg/kg.
• the NAD+ booster is administered to humans at a dosage from 32.52 mg/kg to 8.13 mg/kg.
• the NAD+ booster is administered to humans at a dosage from 24.39 mg/kg to 12.19 mg/kg or 16.26 mg/kg to 12.19 mg/kg. More preferably, the NAD+ booster is administered to humans at a dosage of 15.04 mg/kg.
• the NAD+ booster is Nicotinamide Riboside, or any pharmaceutically acceptable salt thereof, and it is administered at a dosage from 400 mg/kg to 100mg/kg.
• the Nicotinamide Riboside is administered at a dosage from 300 mg/kg to 150 mg/kg or 200 mg/kg to 150 mg/kg. More preferably, the Nicotinamide Riboside is administered at a dosage of 185 mg/kg.
• the NAD+ booster is Nicotinamide Riboside, or any pharmaceutically acceptable salt thereof, and it is administered to humans at a dosage from 32.52 mg/kg to 8.13 mg/kg.
• the Nicotinamide Riboside is administered to humans at a dosage from 24.39 mg/kg to 12.19 mg/kg or 16.26 mg/kg to 12.19 mg/kg. More preferably, the Nicotinamide Riboside is administered to humans at a dosage of 15.04 mg/kg.
• FSL-1 is administered at a dosage up to 1 mg/kg.
• the FSL-1 compound, or a pharmaceutically acceptable salt thereof is administered at a dosage from 1 mg/kg to 0.1 mg/kg.
• the FSL-1 compound is administered at a dosage from 0.75 mg/kg to 0.1 mg/kg or 0.5 mg/kg to 0.1 mg/kg. More preferably, FSL-1 compound is administered at a dosage of 0.25 mg/kg.
• FSL-1 , or a pharmaceutically acceptable salt thereof is administered at a dosage up to 0.08 mg/kg.
• the FSL-1 compound, or a pharmaceutically acceptable salt thereof is administered at a dosage from 0.08 mg/kg to 0.008 mg/kg.
• the FSL-1 compound is administered at a dosage from 0.06 mg/kg to 0.008 mg/kg or 0.04 mg/kg to 0.081 mg/kg. More preferably, FSL-1 compound is administered at a dosage of 0.020 mg/kg.
• the ionizing radiation is gamma (y) rays or X-rays.
• a composition comprising PT and SIL
• the present invention relates to a composition
• a composition comprising a) a Stilbenoid, preferably Resveratrol or Pterostilbene or a salt or derivative thereof, and b) Silibinin, or a salt or derivative thereof.
• the Stilbenoid is Pterostilbene or a salt thereof.
• a second aspect of the invention provides a composition comprising a) Pterostilbene, or a salt thereof, and b) Silibinin, or a salt thereof.
• the composition is a pharmaceutical, nutraceutical, cosmetic or food composition.
• nutraceutical means a "food-drug", i.e. a health food that associates nutritional components with the curative properties of natural active ingredients of proven and recognised effectiveness, in this case PT and SIL.
• compositions include, but are not limited to, liquids such as water, saline, polyethyleneglycol, hyaluronic acid, glycerol and ethanol.
• Pharmaceutically acceptable salts can also be included therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. It is also preferred, that the preparation will contain a pharmaceutically acceptable excipient that serves as a stabilizer, particularly for peptide, protein or other like molecules if they are to be included in the vaccine composition.
• suitable carriers include, without limitation, pharmaceutical grades of dextrose, sucrose, lactose, trehalose, mannitol, sorbitol, inositol, dextran, and the like.
• suitable carriers include, starch, cellulose, sodium or calcium phosphates, citric acid, tartaric acid, glycine, high molecular weight polyethylene glycols (PEGs), and combination thereof.
• PEGs high molecular weight polyethylene glycols
• PTE and SIL can help to facilitate the oral administration of PTE and SIL and are also included herein.
• Some examples include prodrugs (carboxyesters, sulfonates, sulfates, phosphates, acetals, or carbamates or carbonates), nanoemulsions, polyionic/polymeric shells encapsulating nanoparticles, liposomes, or exosomes.
• any pharmaceutically acceptable formulation of PTE and SIL is included herein.
• composition or compositions according to the second aspect comprise PT and SIL in the dosages defined in the first aspect of the invention and it is administered according to the administration route and schedules defined under the first aspect of the invention. Further details and preferred embodiments on the dosage, route and schedules of administration of said composition are also provided under the first aspect of the invention.
• Said composition comprise PT and SIL, or any salts or derivatives thereof, and may further comprise one or more radiomitigator compound/s, as defined under the first aspect of the invention.
• the radiomitigator compound may be NAD+ booster and/or FSL-1.
• the composition comprising PT and SIL further comprises at least two radiomitigator compounds, preferably NR and FSL-1.
• said composition or compositions is in a form suitable for parenteral, oral or topic administration.
• said composition is an aqueous composition, more preferably a stable aqueous composition.
• a “stable composition” may refer to a formulation in which the active ingredient therein essentially retains its physical stability and/or chemical stability and/or biological activity upon storage.
• the composition or compositions of the second aspect can be a food composition.
• the food composition can be a liquid or a solid composition.
• such liquid composition includes, but is not limited to, any beverage selected from the group consisting of animal or plant milk, as well as any derivative thereof, such as for example, milk shakes, yogurt, kefir, etc.; fruit and/or vegetable juices; still water or sparkling water, or flavored or sweetened water or beverages (by means of nutritive sweeteners (sucrose, fructose... ) or artificial sweeteners); seasonings, alcoholic beverages of any type; tea, coffee; as well as all types of refreshing beverages or soft drinks, or energizing beverages.
• any beverage selected from the group consisting of animal or plant milk, as well as any derivative thereof, such as for example, milk shakes, yogurt, kefir, etc.; fruit and/or vegetable juices; still water or sparkling water, or flavored or sweetened water or beverages (by means of nutritive sweeteners (sucrose, fructos
• the food composition can also be a solid composition.
• Such solid composition can, for example, be selected from, but is not limited to, the group consisting of animal or plant milk derivatives, such as cheese, butter, margarine and tofu; any type of bread, including fresh, packaged or frozen bread, sliced bread, wholemeal bread, spiced bread, sweet bread, salty bread, etc; pasta prepared from any cereal flour, such aswheat or semolina flour (macaroni, spaghetti, noodles, etc); baked goods; infusions, tea or coffee, in bulk or insachets, for preparing beverages; jellies, candies, including gummy candies, better known as “soft fruit candies”; as well as any type of solid seasoning, or mixtures thereof.
• animal or plant milk derivatives such as cheese, butter, margarine and tofu
• any type of bread including fresh, packaged or frozen bread, sliced bread, wholemeal bread, spiced bread, sweet bread, salty bread, etc
• pasta prepared from any cereal flour such aswheat
• the food composition can also be a nutritional, dietary or food supplement or complement.
• These terms are normally used for compositions consumed orally, which contain an ingredient intended for complementing the diet, in the case of the present invention, the PT and SIL or any of their salts or derivatives. They shall never replace a conventional food or be the only component of a meal or of the diet.
• the composition may also be nutraceutical compositions.
• the composition may be further used in the preparation of fuctional food or food that have an additional function upon addition of PTE in combination of SIL, as defined throughout the description.
• Nutritional, dietary or nutraceutical compositions or food supplements or functional food can be found in different presentations, such as pastilles, pills, tablets, capsules, soft gelatin capsules, gelatin capsules, wafers, effervescent tablets, liquids (solution, suspension, syrup), granules and powders, all of which are included as particular embodiments within the scope of the present invention. Dietetical ly or pharmaceutically acceptable excipients are obvious for the skilled person for obtaining any of the preceding presentations, and they are included within the scope of the present invention.
• the present invention further relates to said composition for use as defined in the first aspect of the invention.
• a kit of parts comprising PT and SIL
• the present invention relates to a kit of parts comprising at least two recipients comprising at least a) a Stilbenoid, preferably Resveratrol or Pterostilbene, and Silibinin, or any salts or derivatives thereof, and optionally at least one or more radiomitigator compounds as defined above.
• a Stilbenoid preferably Resveratrol or Pterostilbene, and Silibinin, or any salts or derivatives thereof, and optionally at least one or more radiomitigator compounds as defined above.
• the Stilbenoid comprised in the kit of parts is Pterostilbene.
• the two or more ingredients are provided formulated as a composition and provided in two or more separate recipients.
• PT and SIL can be combined in one recipient, and the radiomitigators in the other.
• each compound is contained in a separate recipient.
• the radiomitigator compounds are present in similar recipients as the radiomitigator compounds.
• compositions are as defined in the previous aspects of the invention, for use as defined in the previous aspects of the invention, preferably in the therapeutic treatment of a disease induced by ionizing radiation.
• the present invention relates to a method for preventing, treating, including ameliorating or reducing, diseases induced by ionizing radiation in a subject, comprising administering to a subject a Stilbenoid, preferably Resveratrol or Pterostilbene or a pharmaceutically acceptable salt or derivative thereof, in combination with Silibinin, or any pharmaceutically acceptable salt or derivative thereof.
• a Stilbenoid preferably Resveratrol or Pterostilbene or a pharmaceutically acceptable salt or derivative thereof, in combination with Silibinin, or any pharmaceutically acceptable salt or derivative thereof.
• the Stilbenoid is Pterostilbene.
• the present invention provides a method for preventing, treating, including ameliorating or reducing, diseases induced by ionizing radiation in a subject, comprising administering Pterostilbene in combination with Silibinin, or any pharmaceutically acceptable salts thereof, wherein said administration is performed before the radiation, or after the radiation, or during the radiation; and wherein the combination is herein understood as the simultaneous or sequential administration of a) Pterostilbene, or a pharmaceutically acceptable salt thereof, b) Silibinin, or any pharmaceutically acceptable salt thereof, and optionally, c) at least one or more radiomitigator compounds, as defined throughout the present specification, to said subject. Similar as described above in the first and second aspects of the present invention, the at least one or more radiomitigator compounds may be NAD+ boosters and/or FSL-1 .
• This fourth aspect is related to the first and second aspects described above.
• the compounds and the pharmaceutical compositions, administration dosages, routes and schedules are provided under the previous aspects of the invention and apply herein.
• Pterostilbene in combination with Silibinin for use in nutraceutical field or as a nutraceutical composition.
• the present invention further relates to the use of a Stilbenoid, preferably Resveratrol or Pterostilbene, in combination with Silibinin, or any salt or derivative thereof, or the use of the composition according to the second aspect, wherein said use in the nutraceutical field or as a nutraceutical composition.
• a Stilbenoid preferably Resveratrol or Pterostilbene
• the composition according to the second aspect wherein said use in the nutraceutical field or as a nutraceutical composition.
• the Stilbenoid used is Pterostilbene.
• the fifth aspect provides Pterostilbene, or a salt thereof, in combination with Silibinin, or a salt thereof, for use in the nutraceutical field or as a nutraceutical composition, wherein the combination is herein understood as the simultaneous or sequential administration, in any order, of a) Pterostilbene, or a salt thereof, and b) Silibinin, or a salt thereof, to said subject.
• the use as a nutraceutical composition is for the treatment or prevention of diseases induced by ionizing radiation, for the treatment or prevention of neurodegenerative, cardiovascular, pulmonary, metabolic, or aged-related disorders, and/or for the protection or repairment of the adverse effects of the sun on human skin or lips.
• the term “repairing the adverse effects of the sun on human skin or lips” is used herein to designate arresting, reversing, ameliorating, diminishing, and/or reducing defects, imperfections, or aesthetically unpleasant conditions of the skin, which include, but are not limited to: age spots, sunburn, sun spots, lines, fine lines, wrinkles, crow's feet, spider veins, stretch marks, dark eye circles, hyperpigmentation, hypopigmentation, discoloration, uneven skin tone, dullness, freckles, skin breakout, blemishes, skin fragility, dryness, patchiness, tactile roughness, chapping, sagginess, thinning, enlarged pores, cellulite formation, acne formation, rosacea, psoriasis, and eczema.
• skin includes facial or body skin.
• the diseases induced by ionizing radiation are related to DNA damage, radiation-induced cytotoxicity, genotoxicity and/or oxidative cellular damage. More preferably, the diseases induced by ionizing radiation are selected from the list consisting of acute radiation syndrome and/or chronic radiation syndrome.
• the nutraceutical composition is used in the treatment of a disorder selected from the list consisting of Alzheimer or other dementias or cognitive impairment associated to aging, Parkinson, Huntington disease, Multiple sclerosis, Kennedy disease (Spinal and bulbar muscular atrophy), kidney disease, cerebrovascular disease, hypertension, Chronic obstructive pulmonary disease, Amyotrophic lateral sclerosis and Diabetes.
• a disorder selected from the list consisting of Alzheimer or other dementias or cognitive impairment associated to aging, Parkinson, Huntington disease, Multiple sclerosis, Kennedy disease (Spinal and bulbar muscular atrophy), kidney disease, cerebrovascular disease, hypertension, Chronic obstructive pulmonary disease, Amyotrophic lateral sclerosis and Diabetes.
• This fifth aspect is related to the first and second aspects described above.
• the compounds and the pharmaceutical compositions, administration dosages, routes and schedules are provided under the previous aspects of the invention and apply herein.
• the present invention further relates to the non-therapeutic cosmetic use of a Stilbenoid, preferably Resveratrol or Pterostilbene, in combination with Silibinin, or any salt or derivatives thereof. Further, the sixth aspect also relates to the non-therapeutic cosmetic use of the composition according to the second aspect.
• the Stilbenoid used is Pterostilbene.
• the sixth aspect of the present invention provides Pterostilbene, or a salt thereof, in combination with Silibinin, or a salt thereof, for the non-therapeutic cosmetic use or as a cosmetic composition, wherein the combination is herein understood as the simultaneous or sequential administration, in any order, of a) Pterostilbene, or a salt thereof, and b) Silibinin, or a salt thereof, to said subject.
• non-therapeutic cosmetic use refers to a method used to improve a person's appearance, i.e. , to beautify appearance.
• the used in cosmetics does not involve a treatment by surgery or therapy.
• the cosmetic care includes the topical application of PTE and SIL on the cutaneous areas to be treated.
• the cosmetic use of the composition is with the non-therapeutic purposes of cleaning, beautifying, adding to the attractiveness, altering the appearance, or keeping or promoting the skin or hair in good condition. Said purposes may also be whitening, minimizing the appearance of lines in the face and body, protecting from the sun and sun rays.
• the non-therapeutic cosmetic use is to prevent, reduce and/or ameliorate the natural process of skin aging.
• the non-therapeutic use is to protect, ameliorate and/or reduce the adverse effects of the sun on human skin and lips, including, but not limiting to, age spots, sunburn, sun spots, lines, fine lines, wrinkles, crow's feet, spider veins, stretch marks, dark eye circles, hyperpigmentation, hypopigmentation, discoloration, uneven skin tone, dullness, freckles, skin breakout, blemishes, skin fragility, dryness, patchiness, tactile roughness, chapping, sagginess, thinning, enlarged pores.
• skin includes facial or body skin.
• This sixth aspect is related to the first and second aspects described above.
• the compounds and the compositions, administration dosages, routes and schedules compatible with a cosmetic use and provided under the previous aspects of the invention also apply herein.
• PT+SIL was shown to exert protection against the induced oxidative damage. Further, as shown in Fig. 15, it was found that this mechanism is directly associated with a synergistic increase caused by PTE+SIL in Sirtuins (Sirt) levels, especially Sirtl .
• Sirtuins are a family of signaling proteins involved in metabolic regulation as they control many vital functions, being also involved in several pathologies such as metabolic, cardiovascular, pulmonary diseases, neurodegenerative and age-related disorders, and cancer. Sirtuins have been shown to be modulators of inflammation and autophagy.
• sirtuin-activating or increasing compounds show promise as therapeutic approaches for treating metabolic dysfunction, cancer, and age-related diseases, strongly supporting the use of PTE in combination with SIL for use in the treatment or prevention of said diseases.
• SIL for use in the treatment or prevention of said diseases.
• researchers have showed the role of Sirtuins in neuroprotection, especially in neurodegenerative disorders such as Alzheimer or other dementias or cognitive impairment associated to aging, Parkinson, Huntington disease, Multiple sclerosis, Kennedy disease (Spinal and bulbar muscular atrophy), Amyotrophic lateral sclerosis, and other neuronal-related diseases (see Kim D, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J.
• the present invention a Stilbenoid, preferably Resveratrol or Pterostilbene, in combination with Silibinin, or any salt or derivatives thereof, or a composition according to the second aspect, for use to increase the intracellular levels of Sirtuins in a patient in need thereof, wherein said increase is as compared to the intracellular levels of Sirtuins in the same patient before treatment with the Stilbenoid, preferably Resveratrol or Pterostilbene in combination with Silibinin, or any salt thereof, or before treatment with the composition according to the second aspect.
• the Stilbenoid is Pterostilbene.
• the Sirtuin which intracellular levels are increased is Sirtl , Sirt, 2 or Sirt3, most preferably Sirtl .
• the increase in the intracellular Sirtuin levels as compared to an untreated patient is preferably a statistical significant increase, and it can be measured by any suitable technique aimed at measuring the amount of a protein, such as, but not limited to, Bradford assay, Colorimetric protein measurement BCA, antibody-based assays, such as Western blot or ELISA, Lowry protein assay, fluorescence-based assays, protein mass-spectrometry based assays, nanoparticles and nanopore-based methods, etc.
• the increase of the intracellular levels of Sirtuins is statistically significant when a statistical test is performed to compare it to the basal intracellular levels of Sirtuins in a reference or untreated cell, and wherein the resulting p-value of said statistical test is of 0.1 or lower, preferably 0.05, 0.01 , 0.001 or lower.
• the patient in need thereof is suffering from a disease or disorder characterized by a reduction in the intracellular levels of Sirtuins, preferably a reduction in Sirtl intracellular levels.
• the patient in need thereof is suffering from a neurodegenerative, cardiovascular, pulmonary, metabolic, or aged-related disorders characterized by a reduction in the intracellular levels of Sirtuins, preferably Sirtl , as compared to the intracellular levels of Sirtuins in a healthy person.
• the disorder is selected from the list consisting of Alzheimer or other dementias or cognitive impairment associated to aging, Parkinson, Huntington disease, Multiple sclerosis, Kennedy disease (Spinal and bulbar muscular atrophy), kidney disease, cerebrovascular disease, hypertension, Chronic obstructive pulmonary disease, Amyotrophic lateral sclerosis and Diabetes.
• Pterostilbene, or a salt thereof, in combination with Silibinin, or a salt thereof is used in the treatment, prevention, amelioration or reduction of neurodegenerative diseases, wherein the combination is herein understood as the simultaneous or sequential administration, in any order, of a) Pterostilbene, or a salt thereof, and b) Silibinin, or a salt thereof, to said subject.
• said disorder is characterized by a reduction in the intracellular levels of Sirtuins, preferably Sirtl , as compared to a healthy person.
• the neurodegenerative disorder is selected for the group consisting of Alzheimer or other dementias or cognitive impairment associated to aging, Parkinson, Huntington disease, Multiple sclerosis, Kennedy disease (Spinal and bulbar muscular atrophy), kidney disease, cerebrovascular disease, hypertension, Chronic obstructive pulmonary disease, Amyotrophic lateral sclerosis and Diabetes.
• the cell in which the intracellular levels of Sirtuin, preferably Sirtl , are increased upon treatment is from nervous tissue.
• the cell is a neuron or neuroglia.
• Sirtuins are potential therapeutic targets in the treatment of metabolic disorders, such as diabetes.
• overexpression of Sirtl in pancreatic cells can be used to control of glucemia in diabetic patients (see Nerurkar et al. Respected S ir(2): magic target for diabetes. Cellscience. 2008;4(4):82-96; Moynihan et al. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab. 2005;2(2): 105-117, and Bordone et al. Sirtl regulates insulin secretion by repressing LICP2 in pancreatic beta cells. PLoS Biol.
• a Stilbenoid preferably Resveratrol or Pterostilbene, in combination with Silibinin, or the composition according to the second aspect, can be also used in the treatment, prevention, amelioration or reduction of diabetes.
• the Stilbenoid is Pterostilbene.
• the present invention also provides Pterostilbene, or a salt thereof, in combination with Silibinin, or a salt thereof, for use in the treatment, prevention, amelioration or reduction of diabetes, wherein the combination is herein understood as the simultaneous or sequential administration, in any order, of a) Pterostilbene, or a salt thereof, and b) Silibinin, or a salt thereof, to said subject.
• This seventh aspect is related to the first and second aspects described above.
• the compounds and the pharmaceutical compositions, administration dosages, routes and schedules are provided under the previous aspects of the invention and apply herein.
• the PT in combination with SIL may be administered in a sole composition or in separate compositions.
• the Pterostilbene is Pterostilbene phosphate disodium salt.
• the Silibinin is silibinin-C-2',3-dihydrogen succinate, disodium salt.
• the uses described in any of the above mentioned aspects further comprises the administration of PTE and SIL in combination with at least one further radiomitigator compound, wherein the use described herein is understood as the simultaneous or sequential administration of a) Pterostilbene, or a salt thereof, b) Silibinin, or a salt thereof, and c) one or more radiomitigator compounds, to said subject.
• the at least one or more radiomitigator compound/s refers to a nicotinamide adenine dinucleotide booster (referred from now on as NAD+ boosters), and/or a Fibroblast-Stimulating Lipopeptide-1 (referred from now on as FSL-1 ), or any salt thereof.
• PT and SIL are administered in a subject.
• the subject is a mammal.
• the mammal is a human being, or a domestic animal such as dogs, cats, or horses. More preferably, the mammal is a human being.
• the present invention further provides a method for increasing the intracellular levels of Sirtuins in a subject for preventing, treating, including ameliorating or reducing diseases characterized by having low levels of Sirtuins, or decreased Sirtuin activation, as described in the previous aspects.
• the method comprises administering Pterostilbene in combination with Silibinin, or any salt thereof, wherein the combination is herein understood as the simultaneous or sequential administration of a) Pterostilbene, or a salt thereof, b) Silibinin, or salt thereof, and optionally, c) at least one or more radiomitigator compounds, as defined throughout the present specification, to said subject.
• the at least one or more radiomitigator compounds may be NAD+ boosters and/or FSL-1.
• the dosages and administration routes defined in the first aspect also apply to the uses according to the fifth, sixth, and seventh aspects.
• Pterostilbene, or a pharmaceutically acceptable salt thereof for use in the prevention, amelioration or reduction of diseases induced by ionizing radiation in a subject, in combination with Silibinin, or a pharmaceutically acceptable salt thereof, wherein the administration is carried out before the radiation, or after the radiation, or during the radiation; and wherein the combination is herein understood as the simultaneous or sequential administration, in any order, of a) Pterostilbene, or a pharmaceutically acceptable salt thereof, and b) Silibinin, or a pharmaceutically acceptable salt thereof, to said subject.
• Pterostilbene for use according to clause 1 wherein Pterostilbene and Silibinin, or pharmaceutically acceptable salts thereof, are administered in a sole pharmaceutical composition or in separate pharmaceutical compositions.
• Pterostilbene for use according to any of clauses 1 to 2, wherein the administration of Pterostilbene and Silibinin, or pharmaceutically acceptable salts thereof, is topical, oral or parenteral.
• Pterostilbene for use according to any of clauses 1 to 6, wherein the use further comprises the administration in combination with at least one or more radiomitigator compound/s, wherein the combination is herein understood as the simultaneous or sequential administration of a) Pterostilbene, or a pharmaceutically acceptable salt thereof, b) Silibinin, or a pharmaceutically acceptable salt thereof, and c) at least one or more radiomitigator compound/s, or any pharmaceutically acceptable salt thereof, to said subject.
• Pterostilbene for use according to clause 7, wherein the use further comprises the administration in combination with at least two or more radiomitigator compounds, wherein the at least two or more radiomitigator compounds are NAD+ booster and Fibroblast-Stimulating Lipopeptide, or any pharmaceutically acceptable salts thereof.
• Pterostilbene for use according to any of clauses 1 to 11 , wherein the diseases induced by ionizing radiation are related to DNA damage, radiation-induced cytotoxicity, genotoxicity and/or oxidative cellular damage.
• Pterostilbene for use according to any of clauses 1 to 12, wherein the diseases induced by ionizing radiation are acute radiation syndrome and/or chronic radiation syndrome.
• Pterostilbene for use according to any of clauses 1 to 13, wherein the ionizing radiation is gamma rays or X-rays.
• Pterostilbene for use according to any of clauses 1 -14, wherein the Pterostilbene is Pterostilbene phosphate disodium salt and/or wherein the Silibinin is silibinin-C-2',3-dihydrogen succinate, disodium salt.
• a pharmaceutical composition comprising a) Pterostilbene, or a pharmaceutically acceptable salt thereof, and b) Silibinin, or a pharmaceutically acceptable salt thereof.
• composition according to clause 16 wherein the dosage of Pterostilbene, or a pharmaceutically acceptable salt thereof, present in said composition is from 300 mg/kg to 30 mg/kg, preferably 100 mg/kg, and wherein the dosage of Silibinin, or a pharmaceutically acceptable salt thereof, present in said composition is from 200mg/kg to 35 mg/kg of Silibinin, preferably 70 mg/kg, or the equivalent doses converted to humans.
• composition according to any of clauses 16 and 17, wherein the pharmaceutical composition further comprises at least one or more radiomitigator compound/s, preferably selected from a. NAD+ booster, and/or b. Fibroblast-Stimulating Lipopeptide-1 , or any pharmaceutically acceptable salts thereof.
• radiomitigator compound/s preferably selected from a. NAD+ booster, and/or b. Fibroblast-Stimulating Lipopeptide-1 , or any pharmaceutically acceptable salts thereof.
• composition according to clause 18, wherein the pharmaceutical composition further comprises at least two or more radiomitigators compounds, wherein the at least two or more radiomitigator compounds are a NAD+ booster and Fibroblast-Stimulating Lipopeptide-1 , or any pharmaceutically acceptable salts thereof.
• composition according to any of clauses 18 to 19, wherein the NAD+ booster, or a pharmaceutically acceptable salt thereof, is present in said composition at a dosage from 400 mg/kg to 100 mg/kg, preferably 185 mg/kg, and/or wherein the Fibroblast-Stimulating Lipopeptide-1 , or a pharmaceutically acceptable salt thereof, is present in said composition at a dosage from 1 mg/kg to 0,1 mg/kg, preferably 0.25 mg/kg, or the equivalent doses converted to humans.
• composition according to any of clauses 16 to 21 , wherein said composition further comprises a pharmaceutically acceptable carrier, additive and/or excipient.
• kits of parts comprising at least two recipients comprising at least Pterostilbene and Silibinin, or any pharmaceutically acceptable salts thereof, and optionally at least one or more radiomitigator compound/s.
• a method for preventing, ameliorating or reducing diseases induced by ionizing radiation in a subject comprising administering Pterostilbene in combination with Silibinin, or pharmaceutically acceptable salts thereof, wherein said administration is performed before the radiation, or after the radiation, or during the radiation; and wherein the combination is herein understood as the simultaneous or sequential administration of a) Pterostilbene, or a pharmaceutically acceptable salt thereof, and b) Silibinin, or a pharmaceutically acceptable salt thereof, to said subject.
• mice Male, 9-10 weeks old, 30-32 g were obtained from Charles River Laboratories (Wilmington, MA). This strain is among the most common used in radiation studies (Williams 2010). Mice were fed with a nutritionally complete diet (standard diet, SD) before irradiation. This was A03 from Panlab (Barcelona, Spain), which has 3,200 kcal/kg and the following nutritional composition: crude protein, 23.5%; crude fat, 4.3%; crude fiber, 3.7%; and carbohydrates, 51.1 %; vitamins and minerals were provided as in the NIH-7 open formula for rat and mouse. This diet meets the dietary allowances recommended for adult mice by the American Institute of Nutrition.
• the animals were fed ad libitum and kept in individual metabolic cages, in which body weight and food ingestion were monitored daily.
• the animal room was maintained at 22°C on a 12 h light/12 h dark cycle.
• Ad libitum intake of drinking water was also allowed.
• mice Care of irradiated mice followed the recommendation of the Robert Wood Johnson Medical School (Piscataway, NJ) for mouse total body irradiation (policy 15), which includes: a) use of antibiotics in the drinking water (134 mg ampicillin/kg/day, 40 mg baytril/kg/day, and 220/42 mg sulfamethoxazole/trimethoprim/kg/day), b) making drinking water readibly available, c) Napa nectar Systems Engineering Lab Group Inc., Napa, CA) provided on the bottom of the cage during the first 14 days and replaced daily , d) provision of softened food served in a small Petri dish on the cage floor, e) completely sterile environment (cage, food, and water) to avoid potential immunosuppression-associated infections.
• antibiotics in the drinking water 134 mg ampicillin/kg/day, 40 mg baytril/kg/day, and 220/42 mg sulfamethoxazole/trimethoprim/kg/day
• the irradiation distance from the source was limited to 12 cm. Radiation dosimetry was controlled using alanine dosimeters from Broker (Billerica, MA) with dosimetry variation of +/- 0.09 Gy.
• PTER and SIL Merck Chemicals GmbH, Darmstadt, Germany
• PTER and SIL were solubilized in 2-hydroxypropyl-b- cyclodextrin, then suspended in 0.3% carboxymethylcellulose.
• a PTER salt (pterostilbene phosphate disodium salt, SYNCOM, Groningen, The Netherlands) and SIL salt (silibinin-C-2',3-dihydrogen succinate, disodium salt, Rottapharm/Madaus, Cologne, Germany) were dissolved in sterile vaccination-grade water. All other polyphenolic phytochemicals assayed (Merck Chemicals GmbH; and Cayman Chemical Co., Ann Arbor, Ml) represent main flavonoids and non-flavonoids (Estrela 2017), i.e.
• gallic acid a phenolic acid
• caffeic acid a hydroxycinnamic acid
• curcumin a curcuminoid
• epigallocatechin gallate a flavanol
• genistein a isoflavone
• quercetin a flavonol
• luteolin a flavone
• naringenin a flavanone
• delphindin an anthocyanidin
• phloridzin a chaicone
• NR neurotinamide riboside, 3- aminocarbonyl-1-b-D-ribofuranosyl-pyridinium, Elysium Health, Inc., New York, NY
• FSL-1 InvivoGen, San Diego, CA
• IP Intranet Protocol
• Pharmaceutical grade amifostine was obtained from Cumberland Pharmaceuticals (Nashville, TN) as 500 mg sterile lyophilized powder vial, and reconstituted with physiological saline prior to use.
• mice were removed from the study either dead, moribund, or scheduled for sacrifice. All mice were necropsied, and approx. 30 tissues or organs as well as all gross lesions were collected for microscopic examination. After fixation in 10% neutral-buffered formalin, all tissues were processed routinely and stained with hematoxylin and eosin for histopathological evaluation.
• Femurs were isolated post euthanasia of mice 14 days after the irradiation. Bone marrow cells were flushed from isolated femurs using 26-gauge needle with pre-chilled phosphate-buffered saline. Single cell suspension was prepared by gentle pipetting of the flushed cells few times and number of viable bone marrow nucleated cells (BMNCs) was counted using a hemocytometer (Neubauer, Marienfeld, Germany) and expressed as x10 6 /femur.
• BMNCs viable bone marrow nucleated cells
• Functions of the test include evaluating balance, grip strength and motor coordination of the subjects; especially in testing the effect of experimental drugs.
• Rota Rod Harvard Apparatus, Holliston, MA
• each animal was given three trials and the maximum period (seconds) that it could remain on a rotating axle (3.5 cm diameter; speed of rotation: 15 rpm) without falling was measured.
• Each mouse was given up to three attempts for an arbitrary limit of 1200 seconds and the longest period was recorded. Changes over time in the different groups were monitored weekly.
• MS/MS data acquisition was performed under negative electrospray ionization mode.
• the multiple reaction monitoring mode was employed to monitor SIL with the precursor-to-product ion transition of m/z 481.3/125.0.
• the fragmentary voltage was 150 V, and the collision energy 15 eV.
• Tissue sample preparation was as described for determination of PTER levels (above).
• telomere and centromere staining facilitates the easy detection of dicentrics, centric rings, and acentric chromosomes of premature chromosome condensation in lymphocytes using optimized hybridization conditions and fusion capture of interphase chromosomes.
• This approach presents a major advantage since damage can be observed within hours after blood sampling. Blood was collected 8 h after irradiation as suggested in the procedure (M’kacher 2015), thus allowing time for DNA repair and the occurrence of dicentrics, centric rings, and acentric chromosomes
• Peripheral blood lymphocytes were isolated as described here below.
• Premature chromosome condensation (PCC) was performed as previously described (Pantelias 1983) using CHO cells (ATCC).
• the condensed human chromosomes were distinguished from the CHO chromosomes according to their morphologic characteristics (M’kacher 2015). This procedure required approx. 4 h.
• Telomeres and centromeres of PCC fusions were stained using the Q-FISH technique with a Cy-3-labeled peptide nucleic acid (PNA) probe specific for TTAGGG of telomere and a fluoroscien isothiocyanate-labeled PNA probe specific for centromere sequences (M’kacher 2015) (both from ThermoFisher Scientific, Waltham. MA). Telomere and centromere-stained fusions were automatically recorded using the Autocapt software from Metasystems (Altlussheim, Germany) and a high resolution CCD camera (C91002-23B, Hamamatsu Photonics, Herrsching, Germany).
• the femoral bone marrow was collected from sacrificed mice, and smear was prepared and fixed using methanol. After drying, double staining was performed using May Grunwald and Giemsa stains (Schmid 1975). According to this method, polychromatic erythrocytes (PCE) stained reddish-blue and normochromatic erythrocytes (NCE) stained orange, while nuclear materials were dark purple. The micronucleated polychromatic (MnPCE) and normochromatic (MnNCE) cells were counted out of 2000 cell under oil immersion.
• PCE polychromatic erythrocytes
• NCE normochromatic erythrocytes
• Isolation and incubation of lymphocytes, hepatocytes, and intestinal epithelial cells Isolation of hepatocytes was performed according to previously reported methodology (Berry 1969). Blood mononuclear cells were obtained from heparinized blood by Accuspin-Histopaque (Sigma-Aldrich, St. Louis, MO) gradient centrifugation. Mononuclear cells were washed twice and resuspended in Krebs-Henseleit bicarbonate medium (pH 7.4) with 0.3% bovine serum albumin at a concentration of 20 x 10 6 cells/ml.
• lymphocyte subsets were obtained as previously described (Estrela 1992).
• Isolated hepatocytes were incubated in flasks (about 10 mg dry wt/ml) at 37°C in Krebs-Henseleit bicarbonate medium (KHBM, pH 7.4) containing 1 .3mM-CaCl2, 5%fat- free bovine serum albumin, and in the presence of glucose (5mM).
• the gas atmosphere was O2/CO2 (19:1 ).
• Isolated lymphocytes were incubated (10 6 cells/flask) at 37°C in Krebs-Ringer medium with 5% fat-free bovine serum albumin and in the presence of glucose (5mM) and glutamine (2 mM). After incubation, the cells were disrupted by the addition of 0.2 ml of 25% perchloric acid. Protein was removed by centrifugation and the supernatant was neutralized with 20 ml of a 40% KOH solution and a Tris-(hydroxymethyl) aminomethane/KOH (0.5-2.0 M) solution for the measurement of the metabolites.
• lECs Primary intestinal epithelial cells
• lECs Primary intestinal epithelial cells
• Colon tissue was prepared by removing the longitudinal muscle layer and washing with ice-cold Mg 2+ - and Ca 2+ -free Hank’s Balanced Salt Solution (HBSS) containing 100 II penicillin, 100 pg/ml streptomycin, 25 pg/ml gentamycin and 0.5 mM dithiothreitol (DTT).
• HBSS Hank’s Balanced Salt Solution
• DTT dithiothreitol
• the resulting suspension was passed over a 1000 pm 2 mesh filter.
• Remaining tissue was digested in a buffer containing 75 ll/rnl collagenase type XI (Sigma-Aldrich), 25 pg/ml dispase neutral protease II (ThermoFisher Scientific, Waltham, MA), 0.5 mM DTT, and 2% v/v fetal bovine serum (FBS) (ThermoFisher Scientific) in Dulbecco’s Modification of Eagles Medium (DMEM) (Sigma-Aldrich).
• the digestion buffer containing the tissue was then placed in a 37 °C incubator and allowed to shake at 200 rpm for 2 h.
• the resulting digestion mixture was again passed over a 1000 pm2 filter, and the tissue fragments atop the filter were washed with 25 ml complete growth media (DMEM, 8.5 g/l sodium pyruvate, 2% v/v FBS, 0.25 ll/rnl insulin, 100 II penicillin, 100 pg/ml streptomycin, 25 pg/ml gentamycin, 5 pg/ml transferrin, and 10 ng/ml EGF containing 2% w/v D-sorbitol. Tissue debris remaining in the filter was discarded, and the effluent containing proliferative crypt structures was centrifuged at 200g, for 5 min, at 4 °C.
• DMEM complete growth media
• DMEM 8.5 g/l sodium pyruvate
• 2% v/v FBS 0.25 ll/rnl insulin
• 100 II penicillin 100 pg/ml streptomycin
• the remaining pellet containing isolated intestinal crypts was suspended in DMEM.
• the crypts were suspended in the complete growth media, plated at a density of approximately 2000 crypts/ml/well in a 12-well type I collagen-coated culture dish (ThermoFisher Scientific) and incubated at 37 °C, O2/CO2 (19: 1 ).
• Rates of glucose and glutamine utilization were measured as previously described (Newsholme 1987).
• Isolated hepatocytes were cultured in William’s complete medium at a concentration of 10 6 cells/mL.
• Isolated C2D + lymphocytes were cultured in PB-MAX medium (GIBCO, ThermoFisher Scientific) at a concentration of 2 x 10 6 cells/mL.
• lECs (10 6 cells/mL) were cultured in DMEM supplemented with 10% heat-inactivated FBS, and 300 mg/ml L-glutamine. All cells were cultured at 37°C in a humidified atmosphere of 95% air and 5% CO2.
• Tissue samples were homogenized in 10 mM Tris (pH 7.0) +1 mM EDTA + 150 mM NaCI. Thereafter they were incubated first with RNase A at 37 °C for 30 min and then with proteinase K at 55 °C overnight. This was followed by chloroform/isoamyl alcohol extraction. Samples of 100pg of isolated DNA were digested to nucleosides with nuclease P1 and alkaline phosphatase (Crain 1990). Analysis of modified DNA base 8-hydroxy-2’-deoxyguanosine (8OHdG) was accomplished by UPLC-MS/MS.
• tissue samples were homogenized in 0.1 M phosphate buffer (pH 7.4) + 1 mM EDTA + 0.005% butylated hydroxytoluene.
• Isoprostanes were measured using the 8-isoprostane EIA kit (Cayman Chemical Co.) and following the manufacturer’s protocol.
• Isolated cells were homogenized in 0.1 M phosphate buffer (pH 7.2) at 4 °C.
• y-glu tamylcysteine ligase (GCL), glutathione peroxidase (GPX), catalase (CAT), and superoxide dismutase 1 and 2 (SOD1 and SOD2) activities were measured as previously described in detail (Benlloch 2016).
• Protein concentration was determined with the Pierce BCA protein assay (Thermo Fisher Scientific).
• Glutathione D-L- glutamyl-L-cystenyl-glycine, GSH was determined by LC/MS as previously reported (Obrador 2014).
• GPDH glyceraldehyde 3-phosphate dehydrogenase
• This assay is a single cell gel electrophoresis assay for simple evaluation of cellular DNA damage.
• NPN 14C-nicotinamide mononucleotide
• NAM 14C-nicotinamide
• GE Healthcare Life Sciences Bjdrkgatan, Uppsala, Sweden
• 14C-NMN 14C-nicotinamide
• Cell dispersion was carried out by trypsinization (in Mg 2+_ and Ca2 + ’free PBS supplemented with 0.2% trypsin, 0.5 mM EDTA, and 5 mM glucose for 3 min at 37 °C).
• Cell pellets were obtained by centrifugation (800 g x 5 min at 4 °C), and then 100 pl of phosphate buffer [0.01 M Na2HPO4/NaH2PO4 buffer, pH 7.4, containing protease inhibitor (Sigma- Aldrich)] was added to each cell sample. Samples were further processed, and NAMPT activity was determined on 30 pg of protein as described previously (Elliott GC, et al. 1980, and Schuster S, et al. 2014). Radioactivity (disintegrations/min) was measured using a Tri-Carb® Liquid Scintillation Counter from Perkin-Elmer. Background disintegrations/min from scintillation fluid was subtracted from each measurement.
• mice were sacrificed under aseptic conditions and femurs were isolated on day 7 post irradiation. Bone marrow cells were flushed from the isolated femurs (see above) with phosphate-buffered saline (4 °C) supplemented with 5% fetal bovine serum. Singlecell suspension was passed through 100 pm nylon mesh strainer to remove debris and clumps. Cells were washed twice with phosphate-buffered saline (4 °C) and counted using a hemocytometer.
• Cells were plated ex vivo at a concentration of 5 x 10 4 cells per 35 mm cell culture dish in Methocult GF M3434 (Stemcell Technologies, Vancouver, Canada) growth medium according to the manufacturer’s protocol and incubated for 14 days at 37 °C, 5% CO2, 95% humidity. Colonies were visualized on day 14 of culture using light microscopy (AxioCam MRc5, Zeiss, Oberkochen, Germany) under a polarised light and scanned in a 60 mm gridded scoring Petri dish (Stemcell Technologies). Hematopoietic colony forming cells CFLI-GM and CFU- GEMM were quantified.
• Cell extracts were prepared using the Whole Cell Extraction Kit of Sigma Aldrich.
• the NE-PERTM Nuclear and Cytoplasmic Extraction kit (ThermoFisher Scientific) enables stepwise separation and preparation of cytoplasmic and nuclear extracts from mammalian cells or tissues. Mitochondrial extracts were prepared following the Cell Fractionation and Organelle Isolation procedures standardized by ThermoFisher Scientific.
• the PSilencer 3.1-H1 linear vector from Ambion Inc. (Austin, TX) was used to obtain long term gene silencing.
• a siRNA Oligo Duplex (Locus ID 18037) from Origen (Rockville, MD) was used.
• siRNAs to target mouse Nfe2l2 (RefSeq NM_010902.3), Ppargcl (RefSeq NM_008904.2), Sirtl (RefSeq NM_019812.2), Sirt3 (RefSeq MN_022433.2), Parpl (RefSeq NM_007415.2), SOD2 (RefSeq NM_013671 .3), and GPX1 (RefSeq NM_008160.6) were from Invitrogen. In all cases silencing procedures followed the technical recommendations of the manufacturers.
• Control experiments were performed using equivalent amounts of the corresponding sense oligonucleotides and scrambled oligonucleotides with the same base composition and a randomized sequence. Silencing was confirmed by immunoblotting. Invitrogen Lipofectamine RNAiMAX Transfection Reagent and manufacturer's protocol were used for delivery of siRNA.
• Apoptotic and necrotic cell death were distinguished by using fluorescence microscopy.
• isolated MNs were incubated with Hoescht 33342 (10 mM; which stains all nuclei) and propidium iodide (10 mM; which stains nuclei of cells with a disrupted plasma membrane), for 3 min, and analyzed using a Diaphot 300 fluorescence microscope (Nikon, Tokyo, Japan) with excitation at 360 nm. Nuclei of viable, necrotic, and apoptotic cells were observed as blue round nuclei, pink round nuclei, and fragmented blue or pink nuclei, respectively. About 1 ,000 cells were counted each time.
• Human A549 and MDA-MB-231 cells were from the ATCC (Manassas, VA). Cells were grown in DMEM (Invitrogen, San Diego, CA), pH 7.4, supplemented with 10% heat- inactivated FCS (Biochrom KG, Berlin, Germany), 100 units/mL penicillin and 100 pg/mL streptomycin. Cells were plated (20,000 cells/cm 2 ) and cultured at 37°C in a humidified atmosphere with 5% CO2. Cells were harvested by incubation for 5 min with 0.05% (w/v) trypsin (Sigma Aldrich, St.
• Tumor cells were harvested from culture flasks by exposure to 0.02% EDTA (5 min at 37 °C), washed twice in DMEM, resuspended in the same culture medium, and injected s.c. on the back of the animal (5 x 10 6 cells/mouse). Local tumor growth was determined using calipers every 2 days, starting on the 2nd day of treatment.
• Estrela JM Estrela JM, Hernandez R, Terradez P, Asensi M, Puertes IR, and Vina J. Regulation of glutathione metabolism in Ehrlich ascites tumour cells. Biochem J 286 (Pt 1 ): 257- 262, 1992. Estrela JM, Mena S, Obrador E, Benlloch M, Castellano G, Salvador R, Dellinger RW. Polyphenolic Phytochemicals in Cancer Prevention and Therapy: Bioavailability versus Bioefficacy. J Med Chem. 2017 Dec 14;60(23):9413-9436.
• Glucocorticoid receptor knockdown decreases the antioxidant protection of B16 melanoma cells: an endocrine system- related mechanism that compromises metastatic cell resistance to vascular endothelium-induced tumor cytotoxicity. PloS One. 9, e96466.
• Pantelias GE Maillie HD.
• Patyar RR Patyar S. Role of drugs in the prevention and amelioration of radiation induced toxic effects. Eur J Pharmacol. 2018 Jan 15;819:207-216.
• mice treated with y rays (LD50/30) and pterostilbene (PT) were analysed ( Figure 1 B).
• y rays LD50/30
• pterostilbene PT
• Figure 1 B the thirty-days survival of mice treated with y rays (LD50/30) and pterostilbene (PT) was analysed.
• amifostine 2-(3-aminopropylamino) ethyl
• mice treated with y rays (LD50/30) and resveratrol (Resv) was also analysed and the results are shown in Figure 1 C.
• One Gy absorption of 1 J of energy/kg of matter.
• the results showed that the radioprotective effects of Resv were lower than those of PT.
• gallic acid a phenolic acid
• caffeic acid a hydroxycinnamic acid
• curcumin a curcuminoid
• epigallocatechin gallate a flavanol
• genistein a isoflavone
• quercetin a flavonol
• luteolin a flavone
• naringenin a flavanone
• delphindin an anthocyanidin
• phloridzin a chaicone
• the combination of PT with the different polyphenols resulted in different effects: a) In some cases, the combination resulted in lower survival than the survival provided the PT administrated separately. This is seen, for instance, in the combination of PT with Gallic acid at 60 days post-irradiation. b) In some cases, the survival resulted from the combination of the two compounds was similar to that provided by PT administered alone, indicating that the addition of the other compound barely influenced the overall survival. This is seen, for instance, in the combination of PT with Delphinidin at 60 days post-irradiation. c) In some other cases, the resulting survival equals to approximately the sum of the survivals exerted by the two compounds administered individually.
• Figure 3A shows the Kaplan-Meier curves and LogRank (Mantel-Cox) test (‘comparing the PT+SIL-treated group vs. controls treated with vehicle).
• the IP administration was selected to facilitate the regular administration to a high number of mice.
• the combination of PT+SIL provided long term protection, with around 25% (5/20) survival after 1 year post-irradiation time.
• LogRank Mantel-Cox
• PT and SIL counteract the radiation-induced increase in different oxidative stress-related biomarkers.
• telomeres and centromeres of premature chromosome condensation fusions were stained using the Q-FISH technique.
• the telomeres and centromeres staining was used to score dicentrics, centric rings, and acentric chromosomes from interstitial deletions without telomere staining, acentric chromosomes with only 1 telomere, representing terminal deletions, and acentric chromosomes with 2 telomeres derived from the fusion of 2 acentric chromosomes accompanying the formation of dicentrics or acentric rings.
• DSBs double-strand DNA breaks
• PT and SIL decrease all the radiation-induced cytogenetic alterations, i.e. chromosomal alterations and formation of micronuclei.
• radioprotectors molecules that can reduce the direct damage caused by radiation
• radiomitigators hose that minimize toxicity even after radiation has been delivered
• PT and SIL were combined with the NAD+ booster nicotinamide riboside (NR) and with the toll like receptor 2/6 agonist FSL-1 lipopeptide (FSL-1 )
• NR neurotinamide riboside, 3- aminocarbonyl-1-b-D-ribofuranosyl-pyridinium, Elysium Health, Inc., New York, NY
• FSL-1 fibroblast-stimulating lipopeptide 1 , InvivoGen, San Diego, CA
• NR was administered daily for 30 days, one single dose per day, and starting after the irradiation.
• FSL-1 was administered only once, 24 h after the irradiation.
• the total number of mice used was 20.
• Figure 9 where it is observed that the survival at 60 days post y irradiation provided by each of these molecules administered alone is 0% for NR, 5% for FSL-1 , and 10% for the combination of NR+FSL1 .
• FIG. 11 A shows the administration schedule followed.
• Figure 11 B shows the Kaplan-Meier curves and LogRank (Mantel- Cox) test (‘comparing all groups vs. vehicle-treated controls; +comparing the PT+SIL+NR+FSL1 -treated group vs. the PT+SIL+NR- or the PT+SIL+FSL1 -treated group).
• a synergistic effect was also found when NR and FLS1 were combined with PT and SIL, since the survival of the mice was increased for up to a year.
• the combination of the four components provided protection and survival of up to 90% of the mice treated, showing that the combination of the four component achieves long term survival of irradiated mice.
• mice The causes of death in y irradiated mice (LD50/30) and the effect of the combined administration of the four compounds was studied, as shown in Figure 12.
• the full combination also minimized deaths related to myeloid leukemia and infections/inflammations.
• Lymphocytes (10 3 /pL) 1.4210.15 0.4210.08* 0.9610.11**
• Basophiles (10 3 /pL) 010 010 010 Bone marrow cell count (10 6 cells/femur) 18.811.0 7.410.8* 10.710.9**
• Tumors were irradiated with X-rays (10 Gy) using a 6-keV SL75 linear accelerator from Philips. Single fraction radiotherapy was administered at a rate of 5.0 Gy/min. The protocol for PSNF administration was identical to that explained above, and the radiotherapy was administered on day 21 .
• Statistical analyses were performed using Student’s t-test (P ⁇ 0.01 ; ‘comparing all groups vs. controls; +comparing the y rays+PSNF-treated group vs. the group treated with y rays alone).
• compositions comprising at least PT and SIL, and optionally NR and FSL1 , to protect and mitigate from the damage induced by radiation. It is important to note that the radioprotective of these compounds was extended for long period of times (1 year or longer) as shown in Figure 3A and Figure 11 B.
• EXAMPLE 5 Pterostilbene, silibinin and nicotinamide riboside decrease cellular DNA damage, and FSL1 lipopeptide promotes recovery of the hematopoietic system.
• NR treatment increases the NAD+ content in different cell types and also prevents the decrease of NAD+ induced by y radiation.
• PT+SIL administered alone did not affect the NAD+ levels in any of the cells studied and did not affect the increase elicited by NR (results not shown).
• Administration of FK866, a specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) decreased NAD+ levels in mice treated with PT+SIL+NR or PT+SIL+NR+ y rays (Fig. 14a).
• NAMPT nicotinamide phosphoribosyltransferase
• FSL-1 increases the hematopoietic colony forming cells CFLI-GM (colony forming unit-granulocyte, macrophage) and CFU-GEMM (colony forming unit-granulocyte, erythroid, macrophage, megakaryocyte).
• Nrf2 Nrf2, NF-KB, PGC-1a and PARP1 interactions in the radioprotective mechanism.
• Isolated epithelial intestinal cells were used to investigate potential signaling pathways that may be involved in the protective effect elicited by the combination of PT+SIL.
• PT+SIL exert protection against the y radiation-induced oxidative damage. Presumably, the observed protection is due to induction of Nrf2 (nuclear factor erythroid 2-related factor 2)-dependent antioxidant defenses (Figs. 5-8).
• Nrf2 nuclear factor erythroid 2-related factor 2
• Anti-inflammatory properties have been reported for both polyphenols thus suggesting the involvement of NF-KB (nuclear factor kappa-light- chain-enhancer of activated B cells)-dependent signaling.
• NR-induced increase of NAD+ will also favor PARP1 (Poly [ADP-ribose] polymerase I ndependent DNA repair, sirtuin activity, and PGC-1 a(peroxisome prol iterator-activated receptor y co-activator 1 a) activation.
• PARP1 Poly [ADP-ribose] polymerase I ndependent DNA repair, sirtuin activity, and PGC-1 a(peroxisome prol iterator-activated receptor y co-activator 1 a) activation.
• PT may induce PGC-1 a, Nrf2 activation, and Sirtl expression; whereas SIL could influence Sirt3 expression and PARP1 activity.
• Fig. 15a as compared to controls, both PT and SIL increased nuclear Nrf2 while decreasing nuclear NF-KB levels. In the case of Nrf2, the effect of PT is more pronounced than that exerted by SIL.
• pPGC-1 a was also increased by PT (Fig. 15a).
• Sirtl levels were increased by PT.
• SIL alone did not affect Sirtl levels, the combination of the two polyphenols increased Sirtl levels more than PT alone (Fig. 15a).
• PT and SIL increased Sirt3 levels, although the effect of SIL on Sirt3 was more robust (Fig. 15a).
• Both PT and SIL increased PARP1 (Fig. 15a).
• Fig. 15b outlines the possible molecular interrelationships between these signaling cascades, and the steps where PT and SIL may exert their effects.
• lECs from control or PT+SIL-treated mice, as in Fig. 11 a
• siRNAs to target mouse N bie, Nfe2l2, Ppargcl , Si rt1 , Sirt3, Parpl , S0D2 or GPX1 gene expression facilitate the increase of free NF-KB and the downregulation of all the other molecular targets.
• Isolated lECs were cultured for 24 h in the absence or presence of PT+SIL at concentrations (see the caption of Fig.
• PT and SIL drastically decreased the y irradiation-induced cell death observed in control (vehicle-treated) cells.
• Cell death analysis based on the effect of specific RNAs in cells subjected to y rays, shows that Nrf2, pPGC-1 a, SOD2 and Sirt3 are mainly responsible (Fig. 15d) for the radioprotective effect elicited by the treatment with polyphenols.
• PT and SIL upregulate the antioxidant defenses in different cell types and decrease the y radiation-induced oxidative damage and cytogenetic alterations (chromosomal aberrations and micronuclei formation).
• the protection elicited by PT and SIL may involve different signaling mechanisms which are interrelated. Oxidative stress and inflammation are direct pathophysiological mechanisms activated by exposure of cells to harmful ionizing radiations.
• PT and SIL increase nuclear Nrf2 and the antioxidant response in different cell types (Fig. 15), whereas they decrease NF-DB (Fig. 15) and, presumably, the radiation-associated inflammatory response.
• PT increases Sirtl levels, which facilitates deacetylation of PGC-1 a (Fig. 15).
• PGC-1 a is an inducer of Sirt3 expression, and as shown in Fig. 15, SIL treatment also associates with an increase in Sirt3 levels. Mitochondrial SOD2 (deacetylated by Sirt3) and GSH peroxidase (which depends on the import of GSH from the cytosol) would work to decrease mitochondria-derived ROS and prevent apoptosis activation.
• a gene silencing-based approach identified the pathway linking Nrf2, SirtS and SOD2 as key for the radioprotective effect elicited by the combined treatment with PT and SIL.
• NR generates NAD+ to support Sirtl and SirtS activities and the PARP1 -dependent DNA repair (Fig. 15). PARP1 activity is also induced by both polyphenols (Fig. 15).
• NR a pyridine-nucleoside form of vitamin
• B3 is a precursor to NAD+ with superior pharmacokinetic profile relative to other forms of B3 (nicotinic acid and nicotinamide), therefore it represents an optimum NAD+ booster.
• This work demonstrates that a combination of two radioprotectors, pterostilbene and silibinin, with two radiomitigators, nicotinamide riboside and fibroblast-stimulating lipoprotein 1 , can confer long-term protection of normal tissues against a lethal dose of radiation in mice.
• the established safety profiles of these four molecules clearly warrants continued research to translate this combination for its application in humans.
• Ideal radioprotectors or radiomitigators should be stable, offer the possibility of easy administration, have no relevant systemic toxicity, and protect normal tissues from radiation-induced damages. The proposed combination meets these criteria, while demonstrating high efficacy.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Birds (AREA)
• Dermatology (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Toxicology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Molecular Biology (AREA)
• Emergency Medicine (AREA)
• Gastroenterology & Hepatology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Immunology (AREA)
• Zoology (AREA)
• Marine Sciences & Fisheries (AREA)
• Mycology (AREA)
• Nutrition Science (AREA)
• Food Science & Technology (AREA)
• Polymers & Plastics (AREA)
• Biochemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)
• Cosmetics (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (1)

Family

ID=74205784

Family Applications (1)

Country Status (11)

Cited By (2)

Families Citing this family (1)

Citations (8)

Family Cites Families (7)

• 2021
  • 2021-01-18 EP EP21382036.8A patent/EP4029496A1/en not_active Withdrawn
• 2022
  • 2022-01-18 ES ES22701924T patent/ES3029832T3/es active Active
  • 2022-01-18 PL PL22701924.7T patent/PL4277610T3/pl unknown
  • 2022-01-18 AU AU2022207675A patent/AU2022207675A1/en active Pending
  • 2022-01-18 KR KR1020237028032A patent/KR20230135110A/ko active Pending
  • 2022-01-18 WO PCT/EP2022/051038 patent/WO2022152943A1/en not_active Ceased
  • 2022-01-18 EP EP22701924.7A patent/EP4277610B1/en active Active
  • 2022-01-18 JP JP2023542925A patent/JP2024504645A/ja active Pending
  • 2022-01-18 CN CN202280022392.4A patent/CN117202900A/zh active Pending
  • 2022-01-18 MX MX2023008447A patent/MX2023008447A/es unknown
  • 2022-01-18 CA CA3207734A patent/CA3207734A1/en active Pending
  • 2022-01-18 US US18/271,184 patent/US20250275940A1/en active Pending

Patent Citations (8)

Non-Patent Citations (55)

Also Published As

Similar Documents

Legal Events